A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Michelle Gooey¹, Evelyn Wong², Alisa Pedrana³, Nicole Allard⁴, Joseph Doyle⁵, Margaret Hellard⁶, Amanda Wade⁷

Affiliations

¹ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
² Faculty of Health, Deakin University, 221 Burwood Highway, Burwood, Vic. 3125, Australia.
³ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road,Melbourne, Vic. 3004, Australia.
⁴ Department of Medicine, University of Melbourne, Royal Melbourne Hospital, 300 Grattan Street,Parkville, Vic. 3050, Australia; and WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, 792 Elizabeth Street, Melbourne, Vic. 3000, Australia.
⁵ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, The Alfred and Monash University, Level 2, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
⁶ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road,Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, The Alfred and Monash University, Level 2, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Doherty Institute, 792 Elizabeth Street, Melbourne, Vic. 3000, Australia; and Melbourne School of Population and Global Health, Level 4, 207 Bouverie Street, The University of Melbourne, Vic. 3010, Australia.
⁷ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, Barwon Health, Bellerine Street, Geelong, Vic. 3220, Australia; and Corresponding author. Email: amanda.wade@burnet.edu.au.

PMID: 32693908
DOI: 10.1071/SH19189

Editorial

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Michelle Gooey et al. Sex Health. 2020 Aug.

. 2020 Aug;17(4):387-389.

doi: 10.1071/SH19189.

Authors

Michelle Gooey¹, Evelyn Wong², Alisa Pedrana³, Nicole Allard⁴, Joseph Doyle⁵, Margaret Hellard⁶, Amanda Wade⁷

Affiliations

¹ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
² Faculty of Health, Deakin University, 221 Burwood Highway, Burwood, Vic. 3125, Australia.
³ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road,Melbourne, Vic. 3004, Australia.
⁴ Department of Medicine, University of Melbourne, Royal Melbourne Hospital, 300 Grattan Street,Parkville, Vic. 3050, Australia; and WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, 792 Elizabeth Street, Melbourne, Vic. 3000, Australia.
⁵ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, The Alfred and Monash University, Level 2, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
⁶ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road,Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, The Alfred and Monash University, Level 2, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Doherty Institute, 792 Elizabeth Street, Melbourne, Vic. 3000, Australia; and Melbourne School of Population and Global Health, Level 4, 207 Bouverie Street, The University of Melbourne, Vic. 3010, Australia.
⁷ Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Infectious Diseases, Barwon Health, Bellerine Street, Geelong, Vic. 3220, Australia; and Corresponding author. Email: amanda.wade@burnet.edu.au.

PMID: 32693908
DOI: 10.1071/SH19189

Abstract

In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPs) were surveyed twice to assess hepatitis C knowledge and management; 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22; P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02); however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPs is warranted to ensure optimal hepatitis C management in primary care.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Affiliations

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical